EPISODE · Apr 23, 2026 · 2 MIN
Cannabis Stocks Surge on Federal Reclassification News: What Schedule III Means for Investors
from Cannabis Industry News · host Inception Point AI
In the past 48 hours, the cannabis industry has surged on news of imminent US federal reclassification of marijuana from Schedule I to Schedule III, expected as early as April 23, 2026[1][2][5][7]. This Trump administration move, building on a December executive order, acknowledges medical uses, eases research barriers, and could slash crippling Section 280E taxes from 60 to 80 percent, unlocking banking and investment access[2][5][8]. Stocks exploded Wednesday: AdvisorShares Pure US Cannabis ETF (MSOS) jumped 27 percent to over 5 dollars; Curaleaf soared over 30 percent; Tilray Brands (TLRY) rose 14 percent; Canopy Growth (CGC) climbed 21 percent[1][3]. This dwarfs prior muted reactions to rescheduling talks, signaling investor bets on profitability boosts for multi-state operators like Trulieve and Curaleaf[5][7]. No major new deals, partnerships, or product launches emerged in the last 48 hours, though European M&A accelerates with Canadian producers offloading assets amid price compression[6]. Kentucky advanced medical cannabis with two new cultivators ribbon-cut this week[4]. Hemp faced headwinds: US farmers grew 739 million dollars worth in 2025, up 64 percent year-over-year, but pending THC recriminalization looms[4]. Leaders like Tilray are poised for gains via expanded research and pharma-grade products[2][8]. Consumer shifts remain steady, with no fresh price or supply chain data, though reclassification could stabilize markets long plagued by federal-state clashes. Compared to last week's quiet IRS tip guidance and hemp growth reports, this regulatory pivot marks the biggest catalyst in months, potentially reshaping a fragmented industry into a more investable sector[4]. The National Cannabis Industry Association ramps lobbying May 12 to 14 for broader reform[12]. Volatility persists, as full rules may take 12 to 18 months[1]. (Word count: 298) For great deals today, check out https://amzn.to/44ci4hQ This content was created in partnership and with the help of Artificial Intelligence AI.
What this episode covers
In the past 48 hours, the cannabis industry has surged on news of imminent US federal reclassification of marijuana from Schedule I to Schedule III, expected as early as April 23, 2026[1][2][5][7]. This Trump administration move, building on a December executive order, acknowledges medical uses, eases research barriers, and could slash crippling Section 280E taxes from 60 to 80 percent, unlocking banking and investment access[2][5][8]. Stocks exploded Wednesday: AdvisorShares Pure US Cannabis ETF (MSOS) jumped 27 percent to over 5 dollars; Curaleaf soared over 30 percent; Tilray Brands (TLRY) rose 14 percent; Canopy Growth (CGC) climbed 21 percent[1][3]. This dwarfs prior muted reactions to rescheduling talks, signaling investor bets on profitability boosts for multi-state operators like Trulieve and Curaleaf[5][7]. No major new deals, partnerships, or product launches emerged in the last 48 hours, though European M&A accelerates with Canadian producers offloading assets amid price compression[6]. Kentucky advanced medical cannabis with two new cultivators ribbon-cut this week[4]. Hemp faced headwinds: US farmers grew 739 million dollars worth in 2025, up 64 percent year-over-year, but pending THC recriminalization looms[4]. Leaders like Tilray are poised for gains via expanded research and pharma-grade products[2][8]. Consumer shifts remain steady, with no fresh price or supply chain data, though reclassification could stabilize markets long plagued by federal-state clashes. Compared to last week's quiet IRS tip guidance and hemp growth reports, this regulatory pivot marks the biggest catalyst in months, potentially reshaping a fragmented industry into a more investable sector[4]. The National Cannabis Industry Association ramps lobbying May 12 to 14 for broader reform[12]. Volatility persists, as full rules may take 12 to 18 months[1]. (Word count: 298) For great deals today, check out https://amzn.to/44ci4hQ This content was created in partnership and with the help of Artificial Intelligence AI.
NOW PLAYING
Cannabis Stocks Surge on Federal Reclassification News: What Schedule III Means for Investors
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.